Literature DB >> 9304763

Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes.

W J Shih1, P L Zhao.   

Abstract

Estimation of sample size in clinical trials requires knowledge of parameters that involve the treatment effect and variability, which are usually uncertain to medical researchers. The recent release within the European Union of a Note for Guidance from the Commission for Proprietary Medical Products (CPMP) highlights the importance of this issue. Most previous papers considered the case of continuous response variables that assume a normal distribution; some regarded the portion up to the interim stage as an 'internal pilot study' and required unblinding. In this paper, our concern is with the case of binary response variables, which is more difficult than the normal case since the mean and variance are not distinct parameters. We offer a design with a simple stratification strategy that enables us to verify and update the assumption of the response rates given initially in the protocol. The design provides a method to re-estimate the sample size based on interim data while preserving the trial's blinding. An illustrative numerical example and simulation results show slight effect on the type I error rate and the decision making characteristics on sample size adjustment.

Mesh:

Year:  1997        PMID: 9304763     DOI: 10.1002/(sici)1097-0258(19970915)16:17<1913::aid-sim610>3.0.co;2-z

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Sample size re-estimation in a breast cancer trial.

Authors:  Erinn M Hade; David Jarjoura
Journal:  Clin Trials       Date:  2010-04-14       Impact factor: 2.486

2.  A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Contemp Clin Trials       Date:  2013-04-11       Impact factor: 2.226

3.  An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.

Authors:  Michael Y Mi; Rebecca A Betensky
Journal:  Clin Trials       Date:  2013-01-02       Impact factor: 2.486

4.  Randomized double masked trial of Zhi Byed 11, a Tibetan traditional medicine, versus misoprostol to prevent postpartum hemorrhage in Lhasa, Tibet.

Authors:  Suellen Miller; Carrie Tudor; Vanessa Thorsten; Karma Quzong; Tsering Dekyi; Ty Hartwell; Linda L Wright; Michael W Varner
Journal:  J Midwifery Womens Health       Date:  2009 Mar-Apr       Impact factor: 2.388

5.  Sample size re-estimation in paired comparative diagnostic accuracy studies with a binary response.

Authors:  Gareth P J McCray; Andrew C Titman; Paula Ghaneh; Gillian A Lancaster
Journal:  BMC Med Res Methodol       Date:  2017-07-14       Impact factor: 4.615

6.  Randomised, quadruple blinded, placebo controlled, multicentre trial investigating prophylactic tamsulosin in prevention of postoperative urinary retention in men after endoscopic total extraperitoneal inguinal hernia repair (STOP-POUR trial): a study protocol.

Authors:  Uwe Bieri; Juliette Slieker; Lukas John Hefermehl; Sebastian Soppe; Gerfried Teufelberger; Regula Tedaldi; Nicole Graf; Marco Bieri; Antonio Nocito
Journal:  BMJ Open       Date:  2021-12-07       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.